Media.Player

Calcitonin Gene-Related Peptide For The Reduction Of Allergen-Induced Airway Hyperresponsiveness

Technology Benefits

Treatment of AHR

Technology Application

Treatment of AHR

Detailed Technology Description

Administration of CGRP to sensitized and challenged mice resulted in the normalization of AHR.This potential therapy for AHR was tested in phase II of clinical trials however the trial was never completed.

Supplementary Information

Inventor: Cadieux, Alain
Priority Number: US6743429B2
IPC Current: A61K003823
US Class: 4241981 | 5140119 | 514826 | 514012
Assignee Applicant: Sherbrooke University,Quebec
Title: Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
Usefulness: Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
Summary: CGRP and its natural homolog (their fragments, analogs or derivatives) are useful for the prevention or alleviation of asthma, bronchospastic disease characterized by airway hyperreactivity or lung inflammatory reaction characterized by increased eosinophilia (claimed).
Novelty: Use of calcitonin gene-related peptide for preventing, reducing and/or alleviating bronchospastic airway diseases, especially reversible airway hyperreactivity and lung inflammation encountered in asthma

Industry

Biomedical

Sub Category

Medical Composition

*Abstract

Calcitonin gene-related peptide (CGRP) is a sensory neuropeptide which expression is reduced after allergen challenge in sensitized mice. The same mice develop eosinophilic airway inflammation and airway hyperresponsiveness (AHR). Scientists at National Jewish Health have shown that administration of CGRP to sensitized and challenged mice resulted in the normalization of AHR.

*Principal Investigator

Name: Erwin Gelfand, Chairman

Department: Department of Pediatrics

Country/Region

USA